Germline mutations in fundamental epigenetic regulatory molecules including DNA methyltransferase 3A (DNMT3A) are commonly associated with growth disorders, whereas somatic mutations are often associated with malignancy. We profiled genome-wide DNA methylation patterns in DNMT3A c.2312G>A; p.(Arg771Gln) carriers in a large Amish sibship with Tatton-Brown-Rahman syndrome (TBRS), their mosaic father and 15 TBRS patients with distinct pathogenic de novo DNMT3A variants. This defined widespread DNA hypomethylation at specific genomic sites enriched at locations annotated to genes involved in morphogenesis, development, differentiation, and malignancy predisposition pathways. TBRS patients also displayed highly accelerated DNA methylation aging. Notably, these findings were most striking in a carrier of the AML associated driver mutation p.Arg882Cys. Our studies additionally defined phenotype related accelerated and decelerated epigenetic aging in two histone methyltransferase disorders; NSD1 Sotos syndrome overgrowth disorder and KMT2D Kabuki syndrome growth impairment. Together, our findings provide fundamentally new insights into aberrant epigenetic mechanisms, the role of epigenetic machinery maintenance and determinants of biological aging in these growth disorders.
Introduction
DNA methylation is an essential epigenetic process involving the addition of a methyl group to cytosine. It is known to play a role in many important genomic regulatory processes, including X-chromosome inactivation, genomic imprinting and the repression of tumor suppressor genes in cancer, mediating transcriptional regulation as well as genomic stability (Jones 2012) . Three catalytically active DNA methyltransferases (DNMTs) are involved in the methylation of cytosine: DNMT1, which is mainly responsible for the maintenance of DNA methylation over replication and DNMT3A and DNMT3B, which generally perform de novo methylation of either unmethylated or hemimethylated DNA. An absence of these enzymes in mice results in embryonic (DNMT1 and 3B) or postnatal (DNMT3A) lethality (Okano et al. 1999) , confirming their essential roles in development. In line with knockout mouse models, pathogenic variants affecting the chromatin binding domains of DNMT1 have been shown to cause two separate progressive autosomal dominant adult-onset neurologic disorders (Klein et al. 2011) . Biallelic pathogenic variants in DNMT3B have been associated with immunodeficiency, centromere instability and facial anomalies (ICF) syndrome (Jiang et al. 2005) . To date, DNMT3A has been linked to a number of physiological functions, including cellular differentiation, malignant disease, cardiac disease, learning and memory formation. Somatically acquired pathogenic variants in DNMT3A are associated with over 20% of acute myeloid leukemia (AML) cases, whilst heterozygous germline pathogenic variants have more recently been found to underlie Tatton-Brown-Rahman syndrome (TBRS; also known as DNMT3A-overgrowth syndrome, OMIM: 615879) (Challen et al. 2011; Tatton-Brown et al. 2014) . TBRS is characterized by increased growth, intellectual disability (ID) and dysmorphic facial features.
There is an emerging group of epigenetic regulatory molecule-associated human growth disorders where the underlying molecular defect is a disruption to the DNA methylation and histone machinery. There are now over 40 disorders identified within this group, which can be further subgrouped into diseases resulting from disruption of the 'writers ', 'readers' and 'erasers' of epigenetic modifications (Bjornsson 2015) . Example disorders in each group include Kabuki, Sotos and Weaver syndromes ('writers'), Smith-Magenis, Rett and Bohring-Optiz syndromes ('readers'), and Wilson-Turner and Cleas-Hensen syndromes ('erasers'). The final subgroup occurs due to disruption of chromatin remodellers, with example resulting disorders including CHARGE and Floating Harbour syndromes. Neurological and cognitive impairment are common features of these conditions, suggesting that precise epigenetic regulation may be critical for neuronal homeostasis. However, a true understanding of the pathogenic mechanism underlying these conditions remains poorly understood.
In the current study, we investigated the methylomic consequences of a DNMT3A pathogenic variant (NC_000002.12:g.25240312C>T; NM_022552.4:c.2312G>A; p.Arg771Gln) in a large Amish family comprising four individuals affected with TBRS arising due to a mosaic pathogenic DNMT3A variant in their father (Xin et al. 2017) . The occurrence of multiple affected and unaffected individuals in the same sibship, together with the combined genetic and environmental homogeneity of the Amish, permitted an in-depth investigation of the genomewide patterns of DNA methylation associated with pathogenic variation in DNMT3A. We subsequently extended our analyses to other (non-Amish) TBRS patients harbouring distinct pathogenic de novo DNMT3A variants, as well other methyltransferase associated overgrowth and growth deficiency syndromes, defining altered epigenetic profiles as common key themes of these growth disorders.
Results
Reduced DNA methylation at sites involved in morphogenesis, development and differentiation in TBRS patients DNMT3A encodes a DNA methyltransferase with both de novo and maintenance activity (Okano et al. 1999; Chen et al. 2003) . We first looked for global changes in DNA methylation in whole blood obtained from DNMT3A c.2312G>A; p.(Arg771Gln) carriers, using the methylationsensitive restriction enzyme based LUMA assay (Karimi et al. 2006) Figure S1 ), of which 1,776 DMPs were characterized by a >10% change in DNA methylation. Interestingly, these DMPs were highly enriched for sites characterized by reduced DNA methylation in DNMT3A c.2312G>A; p.(Arg771Gln) heterozygotes (n = 2,576 DMPs, 98.85%, sign-test p-value < 2.2x10 -16 ). We examined the extent to which these findings were potentially driven by cell-type differences between DNMT3A c.2312G>A; p.(Arg771Gln) carriers and wildtype family members using derived blood cell-type estimates from each sample (Horvath 2013) . There was a highly significant correlation (r = 0.876, p-value < 2.2x10 -16 , Supplemental Figure S2 ) in effect sizes at the 2,606 DMPs 7 between models including and excluding cell-types as covariates, indicating that the observed patterns of differential DNA methylation are not strongly influenced by cell-type variation. We used DMRcate (Peters et al. 2015) to identify spatially correlated regions of differential DNA methylation significantly associated with the DNMT3A c.2312G>A; p.(Arg771Gln) variant, identifying 388 autosomal differentially methylated regions (DMRs) (example DMR shown in Supplemental Figure S3 ), all characterized by hypomethylation in DNMT3A c.2312G>A; p.(Arg771Gln) carriers apart from one 739bp DMR which showed increased DNA methylation (Supplemental Table S2 ). The mean size of the identified DMRs was 625bp (range = 6 to 5,522bp), spanning an average of 6 probes (Supplemental Figure S4) . 
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We next investigated whether DNMT3A p.(Arg771Gln)-associated DMPs are enriched in specific genic locations (see Methods). We found a modest enrichment of DMPs in regions 1500bp or more upstream of the transcriptional start site (Chi-Squared Yates corrected p-value=0.047) and more prominent enrichment in intergenic regions (Chi-Squared Yates corrected p-value=1.54x10 -14 ) (Supplemental Figure S5A ). DMPs were also significantly enriched in CpG Island shore regions (Chi-Squared Yates corrected p-value=8x10 -30 ) (Supplemental Figure S5B ). We also examined DMP occurrence in experimentally determined cancer and reprogramming specific DMR locations (Doi et al. 2009 ), finding a 2.4 fold and 4.7 fold overrepresentation (Chi-Squared Yates corrected p-value=4.24x10 -6 and Chi-Squared Yates corrected p-value<1.3x10 -41 respectively), as well as predicted enhancer elements which showed a 1.4 fold overrepresentation (Chi-Squared Yates corrected p-value=7.57x10 -16 ). We then undertook gene ontology analysis, accounting for the background distribution of probes on the Illumina 450K array, to functionally annotate the DNA methylation differences observed in the carriers. The 2,606 DMPs identified in this study showed significant overrepresentation in functional pathways related to morphogenesis, development and differentiation (top hit: GO:0007275 -multicellular organism development, contains 474 genes associated with DMPs, FDR Q-value=3.7x10 -7 ) ( Supplemental Table S3 ).
To provide additional evidence to support the notion that DNMT3A c.2312G>A; p.(Arg771Gln) carriers exhibit disruption to developmental pathways, we used the Genomic Regions 
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Altered epigenetic aging in methyltransferase-associated human growth disorders
To determine whether altered epigenetic aging is a characteristic of other growth disorders associated with disruption of epigenetic regulatory molecules, we extended our study using publicly-available Illumina 450K DNA methylation data. We first analysed the data from patients with Sotos syndrome, a congenital overgrowth syndrome which results from mutation of the epigenetic modifier NSD1 ( Supplemental Table S4 ), a lysine histone methyltransferase, (Kurotaki et al. 2002; Qiao et al. 2011) . Notably, consistent with DNMT3A pathogenic variant carriers, these individuals are characterized by an epigenetic age acceleration of ~40% (linear regression model R 2 =0.869, p-value=6.4x10 -9 ) (see Figure 3b ). We then examined data from patients with loss of function variants in the KMT2D gene ( Supplemental Table S5) The majority of DNMT3A pathogenic variants in TBRS have been found to be de novo, with five individuals inheriting the pathogenic variant from two mosaic parents (Tlemsani et al. 2016; Xin et al. 2017) and two individuals inheriting the pathogenic variant from their affected father (Lemire et al. 2017) . Extensive studies of the role of DNMT3A in haematopoietic stem cell (HSC) differentiation are also reported, including the regular occurrence of somatic DNMT3A variants in patients with acute myeloid leukaemia (AML). The most common somatic pathogenic variant reported in patients with AML affects the amino acid residue Arg882. To date, pathogenic variation at this residue has been described in the germline of 12 TBRS patients, five with p.(Arg882His) and seven with p.(Arg882Cys) (Tlemsani et al. 2016; Hollink et al. 2017; Kosaki et al. 2017; Shen et al. 2017; Spencer et al. 2017; Tatton-Brown et al. 2018 ). Despite 1 9
these studies, the underlying biological mechanism and outcomes of gene mutation in TBRS, and the potential risks of haematological malignancy, remain largely unclear.
Here we investigated variation in DNA methylation associated with a germline heterozygous Remarkably we defined clear aberrations in epigenetic aging appropriate to the specific nature of each condition. In both overgrowth conditions, TBRS and Sotos syndrome, we identified accelerated epigenetic aging as measured by the DNA methylation age calculator (Horvath 2013 ). Conversely patients with Kabuki syndrome clinically characterized by poor growth, displayed decelerated epigenetic age. Epigenetic age has been strongly correlated with chronological age in unaffected individuals in previous studies of a variety of tissue types (Hannum et al. 2013; Horvath 2013) . The observation of accelerated epigenetic aging in both TBRS and Sotos syndrome potentially results from reduced methyltransferase activity, in 2 0 addition to increased cell turnover associated with the overgrowth seen with these disorders, with the converse being the case for Kabuki syndrome. Accelerated epigenetic aging has been associated with age-related clinical characteristics and mortality in epidemiological studies. For example, accelerated epigenetic age in lymphocytes correlates with reduced physical and cognitive function in the elderly, and increased overall mortality independent of other variables such as BMI, sex and smoking status (Marioni et al. 2015; Chen et al. 2016) . Accelerated epigenetic age has also been found in specific diseases such as Huntington's disease (+ 3.4 years) (Horvath et al. 2016 ), Down's syndrome (+ 6.6 years) and Werner's syndrome (+ 6.4 years) (Maierhofer et al. 2017 individuals may vary depending on the specific pathogenic variant underling their condition (Hollink et al. 2017) . The significantly advanced epigenetic age that we observed in association with p.Arg882Cys may explain why haematological malignancy has to date only been reported in two TBRS patients, one harbouring this germline variant and the second the p.Tye735Ser variant, the latter not being assessed in this study (Hollink et al. 2017; Tatton-Brown et al. 2018 ).
In summary, our findings identify widespread DNA hypomethylation in genes involved in morphogenesis, development, differentiation and malignancy in TBRS patients. These findings provide important new insights into the role of DNMT3A during development, and of relevance to haematological malignancy, and define perturbation to epigenetic machinery and biological ageing as common themes i n overgrowth and growth deficiency syndromes.
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Methods
Genetic and Clinical Studies
The phenotypic features of the four affected siblings (3 females and 1 male, aged 11-25 years; Figure 1a individuals III:3, III:5, III:7 and III:13) include: macrocephaly, tall stature, obesity, (Chen et al. 2013; Price et al. 2013) . Differentially methylated positions (DMPs) were identified using a limma based linear model based on pathogenic variant genotype and sex as a covariate (Smyth 2004) . Significance was determined using the Benjamini-Hochberg false discovery rate (FDR) of 5% (Benjamini and Hochberg 1995) . Changes in methylation were calculated based on comparison between DNMT3A c.2312G>A; p.(Arg771Gln) carriers vs wildtype individuals in the Amish pedigree. The additional 15 DNMT3A pathogenic variants were assessed relative to 7 anonymous control samples run on the same EPIC array run. Blood cell counts were unknown and so were estimated using the DNA methylation age calculator (Horvath 2013; Koestler et al. 2013) , and assessed in the linear model. To identify differentially methylated regions (DMRs), the package DMRcate was used with the same limma based design (Peters et al. 2015) . Gene ontology enrichment analysis was performed using genes annotated to FDR corrected differentially methylated positions using the gometh function of the missMethyl package (Phipson et al. 2016 ) which takes into account potential bias of probe distributions on the beadchip array. KEGG pathway analysis was performed using the gsameth command of missMethyl and KEGG annotation files from the Bioconductor KEGGREST package (http://bioconductor.org/packages/release/bioc/html/KEGGREST.html). Regional enrichment analysis based on Illumina annotations was performed using a Chi-squared test with
Yates correction in R. Differentially methylated regions were functionally annotated using the webtool GREAT (http://great.stanford.edu/public/html/).
Global methylation measurements were made using the Luminometric methylation assay (LUMA) (Karimi et al. 2006 ) based on cleavage by a methylation sensitive restriction enzyme followed by polymerase extension assay via pyrosequencing on the Pyromark 24 (Qiagen).
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Epigenetic age calculations were made using the DNA methylation age calculator et al. 2015) . Kabuki syndrome DNA methylation data and chronological age was obtained from GEO accession GSE97362 (Butcher et al. 2017 ).
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